Study for AZD4360 in Participants With Advanced Solid Tumours

Exclusion Criteria

• •1. Human Epidermal Growth Factor Receptor 2 (HER2) positive (3+ by IHC or 2+ by IHC and positive by in situ hybridisation) or indeterminate G/GEJC participants.
• •2. Unstable or active peptic ulcer disease or digestive tract bleeding including but not limited to clinically significant bleeding in the setting of prior CLDN18.2 directed therapy.
• •3. Participants with clinically significant ascites that require drainage.
• •4. Central nervous system (CNS) metastases or CNS pathology, as defined by protocol.
• •5. With spinal cord compression or with high risk of paralysis.
• •6. History of non-infectious interstitial lung disease/pneumonitis.
• •7. Participant has cardiac abnormalities, as defined by protocol.
• •8. History of another primary malignancy within 2 years prior to screening.
• •9. Known serologic status reflecting active hepatitis B or hepatitis C.
• •10. Known HIV infection that is not well controlled.
• •11. Active tuberculosis infection.